Cantor Fitzgerald Issues Positive Estimate for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at Cantor Fitzgerald raised their FY2025 earnings estimates for Arrowhead Pharmaceuticals in a research note issued on Tuesday, May 13th. Cantor Fitzgerald analyst P. Agrawal now expects that the biotechnology company will post earnings per share of ($0.54) for the year, up from their prior forecast of ($4.20). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

Several other equities research analysts have also recently commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. B. Riley restated a “buy” rating and set a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $42.13.

Arrowhead Pharmaceuticals Stock Up 2.9%

NASDAQ:ARWR opened at $15.34 on Thursday. The stock has a 50-day simple moving average of $13.29 and a 200 day simple moving average of $17.83. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $30.41. The company has a market cap of $2.11 billion, a PE ratio of -2.97 and a beta of 0.89. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same quarter last year, the company posted ($1.02) EPS.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 40,322 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total transaction of $406,042.54. Following the completion of the transaction, the chief executive officer now owns 4,022,055 shares in the company, valued at approximately $40,502,093.85. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 275,880 shares of company stock worth $4,034,037. Insiders own 4.30% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. First Citizens Bank & Trust Co. bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $205,000. KBC Group NV raised its position in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the period. Pacer Advisors Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 11.6% during the 4th quarter. Pacer Advisors Inc. now owns 27,918 shares of the biotechnology company’s stock worth $525,000 after buying an additional 2,907 shares during the last quarter. R Squared Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $38,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Arrowhead Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,385 shares of the biotechnology company’s stock worth $496,000 after buying an additional 2,475 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.